Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (NASDAQ:BIIB) shares experienced a change in market expectations as Cantor Fitzgerald revised the company's price target. The new target has been set at $206.00, a decrease from the previous ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...

The Payment Card Industry Data Security Standard’s 4.0 requirements are designed to protect card information from theft or ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 36 tables and 83 figures, this 153-page report ?North America Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Appeal Nos. 2024-1965, -1966, -2082, -2083 (Fed. Cir. Jan. 29, 2025) ...

As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

Brightcove's deal is one of several large acquisitions of local technology companies expected to close in 2025. Those include Markforged, which is set to be acquired by Waltham's Nano Dimension, and ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Wall Street trading got off to a mixed start early on Wednesday as share price losses at tech giants Alphabet and AMD put ...